Didier Saurigny

Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

Peter C. Taylor, Didier Saurigny, Jiří Vencovský et al. · Arthritis Research & Therapy · 2019 · 89 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study

Christopher D. Buckley, Jesus Abraham Simón Campos, Brandon Becker et al. · The Lancet Rheumatology · 2020 · 44 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13

Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase IIa study

Tsutomu Takeuchi, Yoshiya Tanaka, D. Close et al. · Modern Rheumatology · 2014 · 39 citations

Medicine, Internal Medicine, Pharmacotherapy +17

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

T. Huizinga, Anastas Batalov, Elisabeth A. Lloyd et al. · Arthritis Research & Therapy · 2017 · 35 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)

Roy Fleischmann, Désirée van der Heijde, Vibeke Strand et al. · Annals of the Rheumatic Diseases · 2023 · 35 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17